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Background and purpose   Should blockade of TNF-α be avoided 
after orthopedic surgery? Healing of injuries in soft tissues and 
bone starts with a brief inflammatory phase. Modulation of 
inflammatory signaling might therefore interfere with healing. 
For example, Cox inhibitors impair healing in animal models of 
tendon, ligament, and bone injury, as well as in fracture patients. 
TNF-α is expressed locally at increased levels during early heal-
ing of these tissues. We therefore investigated whether blocking 
of TNF-α with etanercept influences the healing process in estab-
lished rat models of injury of tendons and metaphyseal bone. 
Methods   Rats were injected with etanercept, 3.5 mg/kg 3 times 
a week. Healing of transected Achilles tendons and bone healing 
around screws implanted in the tibial metaphysis were estimated 
by mechanical testing. Tendons were allowed to heal either with 
or without mechanical loading. Ectopic bone induction following 
intramuscular BMP-2 implants has previously been shown to be 
stimulated by etanercept in rodents. This was now tested as a posi-
tive control.
Results   Tendon peak force after 10 days was not signifi-
cantly influenced by etanercept. Changes exceeding 29% could 
be excluded with 95% confidence. Likewise, screw pull-out force 
was not significantly influenced. More than 25% decrease or 
18% increase could be excluded with 95% confidence. However, 
etanercept treatment increased the amount of bone induced by 
intramuscular BMP-2 implants, as estimated by blind histologi-
cal scoring.
Interpretation   Etanercept does not appear to impair tendon or 
metaphyseal bone healing to any substantial degree.

 
Inflammation is an important part of early healing of both bone 
and soft tissues. Several inflammatory mediators are known 
to be expressed and to influence tissue healing. Non-steroidal 
anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenases 
and direct eicosanoid synthesis from prostaglandins towards 
leukotrienes (Cottrell and O’Connor 2009). It has been known 
for decades that these drugs inhibit fracture repair in animal 
models; later, it was shown that they also inhibit tendon and 
ligament healing (Elder et al. 2001, Virchenko et al. 2004). It 
has also been shown that NSAIDs increase the risk of heal-
ing complications in patients with high-energy fractures (Burd 
et al. 2003). Clinicians now take this into account and avoid 
using NSAIDs in cases where bone healing might become 
problematic. Corticosteroids inhibit fracture healing in animal 
experiments, possibly through its anti-inflammatory action 
(Waters et al. 2000, Doyon et al. 2010). Other drugs that mod-
ulate inflammatory mediators, such as modulators of tumor 
necrosis factor α (TNF-α) signaling, have not been studied 
much in the fracture healing context. 
TNF-α is expressed during fracture healing (Kon et al. 
2001). Also, we have noted strong TNF-α expression during 
early tendon healing, and that mechanical loading can reduce 
this expression (Eliasson et al. 2009a). There are few data 
available on how modulation of TNF-α signaling influences 
repair. Systemic treatment with TNF-α was found to reduce 
the amount of cartilage formed in rib fractures in rats (Hashi-
moto et al. 1989), and antagonizing the effect of TNF-α with 
etanercept increased bone formation in bone morphogenic 
protein-2 (BMP-2) implants in mice (Eguchi et al. 2010). Mice 
unable to express TNF-α receptor p55/p75 have delayed car-
tilage resorption during endochondral fracture healing (Ger-
stenfeld et al. 2003). TNF-α signaling appears to be required 
for normal membranous ossification, as this type of bone for-
mation is reduced in receptor knockout mice (Gerstenfeld et 
al. 2001). Recently, it was suggested that TNF-α was crucial 
for recruiting muscle-derived stem cells (MSCs) into fracture 
hematomas in a mouse delayed-union model (Glass et al. 
2011). The same article also briefly described a positive effect 
on mouse tibial fracture healing of local injections of TNF-α 
on day 0 and 1 after fracture, as measured on day 28. Although 
studies with receptor knockouts or local injection of TNF-α 
can give mechanistic insights, they may not be ideal for pre-
dicting the effects of etanercept treatment. 
Clinically, fractures in metaphyseal bone, which heal 
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more common than diaphyseal fractures, which heal partly by 
endochondral repair. Ruptures in soft collagenous tissues are 
also common. Because the in vivo functions of TNF-α appear 
complex, even a detailed knowledge of its effects at the cel-
lular level is probably insufficient to be able to accurately pre-
dict the consequences of changing TNF-α signaling during a 
healing process. We therefore studied the effects of etanercept 
on tendon healing and endosteal membranous ossification in 
vivo using validated rat models, where the results of both of 
these processes can be tested mechanically. 
Short, early NSAID treatment can impair healing. It appears 
that early inflammation may be necessary to trigger healing, 
while late inflammation could be deleterious (Virchenko et al. 
2004). We therefore tested etanercept treatment both in the 
early phase and later in separate groups. Because etanercept 
has been shown to increase bone formation in intramuscular 
BMP-2 implants (Eguchi et al. 2010), we used that model as 
a form of positive control to demonstrate that the etanercept 
regime was adequate.
 
Material and methods
Experimental overview
We used 110 rats in 3 different experiments, evaluating the 
effects of etanercept treatment on healing of transected Achil-
les tendons, on healing of metaphyseal bone injury due to 
screw insertion, and on intramuscular bone formation in 
response to BMP-containing collagen implants. 
Animals, anesthesia, and dosing
The experiments were approved by the regional ethics com-
mittee for animal experiments and we followed the insti-
tutional guidelines for care and treatment of experimental 
animals. The animals were randomly allocated to treatment 
groups with 10 in each (10-week-old Sprague-Dawley rats 
(Taconic, Lille Skensved, Denmark)). They shared cages in 
groups of 2 to 4, with 12-h light/dark cycles, a room tempera-
ture of 21˚C, and free access to food and water. They were 
killed using CO2 gas. 
During surgery, all animals were anesthetized with 5% 
isoflurane gas, prior to which they were given 25 mg/kg tet-
racycline as antibiotic. As analgesic, 0.045 mg/kg buprenor-
phine was given before surgery and after 12 and 24 h. The 
surgery was performed under aseptic conditions as previously 
described (Wermelin et al. 2008, Andersson et al. 2009). Sur-
geons and evaluators were blinded as to treatment. 
The dosage of etanercept (Enbrel; Wyeth) was always 3.5 
mg per kg body weight. Rats receiving etanercept on day 0 
were given it 1 h before the operation. 
Tendon transection experiment
The effect of etanercept on Achilles tendon healing was stud-
ied in 40 female rats. Half of the rats received botulinum toxin 
injections (Botox; Allergan, Irvine, CA) into the calf muscles 
of their right hind leg 5 days before surgery, in order to study 
healing under different loading conditions. 3 injections of 1 U 
each (total injected volume 0.06 mL) were administered. All 
animals developed an obvious limp that remained for the dura-
tion of the experiment. 
During the surgical procedure, the right Achilles tendon 
was exposed and a 3-mm segment was removed. The plan-
taris tendon was removed entirely and the Achilles tendon 
left unsutured (Eliasson et al. 2009b). Etanercept was given 
on days 0, 2, 5, and 8, or not at all. The animals were killed 
on day 10, and the strength of the healing tendon was mea-
sured.
Metaphyseal screw experiment
The effect of etanercept on metaphyseal bone healing was 
assessed in 40 male rats by mechanical pull-out testing of 
an implanted screw. An 8- to 9-mm incision was made along 
the left proximal tibia. A 1.4-mm hole was then drilled, 
approximately 3 mm from the physis. Thereafter, a stainless 
steel screw, 1.6 mm in diameter, was inserted as previously 
described (Wermelin et al. 2008). Etanercept was adminis-
tered on days 0 and 2, days 5, 8, and 11, days 0, 2, 5, 8, and 
11, or not at all. The animals were killed and pull-out force, 
stiffness, and energy measured on day 14. 
Intramuscular implant experiment 
As an indicator of the biological effect of the etanercept dose 
chosen, 30 male rats received a collagen carrier with 30 µg 
rh-BMP-2 inserted into an abdominal muscle pouch created 
between the inner and outer oblique muscle layers, just lateral 
to the rectus sheath. A 3 × 2.5 × 5 mm collagen sponge (Heli-
stat; Colla-Tec Inc., Plainsboro, NJ) was soaked with 10 µL 
0.2 mM acetic acid containing 30 µg of rh-BMP 2 (GenScript, 
Piscataway, NJ) and inserted into the pouches (Aspenberg and 
Turek 1996). Etanercept was given on day 0 and 2, on days 0, 
2, 5, 8, and 11, or not at all. The animals were killed on day 
14. Bone formation in the implants was assessed by radiology 
and histology.
Mechanical evaluation
Mechanical evaluation was performed using a computerized 
materials testing machine (100R; DDL Inc., Eden Prarie, 
MN). The crosshead speed was 0.1 mm/s. Samples were kept 
moist and evaluated within an hour after harvest. Peak force 
(N) was considered the primary effect variable. The energy 
(Nmm) absorbed until the force reached its peak value was 
measured for the tendons. For screw pull-out testing, the 
energy absorbed until the force dropped to 90% of the peak 
value was measured instead. Stiffness (N/mm) was recorded 
for both. Methods for tissue mounting in the testing machine 
have been described (Virchenko et al. 2004, Wermelin et al. 
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Radiographic analysis
The collagen BMP implants could be identified by transillu-
mination of the abdominal wall. Thereafter, the pieces were 
trimmed down, fixed in buffered formalin, and radiographed 
(MX-20; Faxitron X-ray Corp., Chicago, IL). The pictures 
were analyzed by image processing using 2 arbitrarily chosen 
thresholding levels. These levels were the same for all sam-
ples. A lower threshold was used to estimate the total area of 
the ossicle, and a higher threshold to estimate mineral content 
(ImageJ Software; NIH, Bethesda, MD).
Histology
Following radiographic evaluation, the collagen BMP 
implants were decalcified, paraffin embedded, and prepared 
for histology with hematoxylin and eosin staining. The slides 
were assessed by blinded qualitative scoring and given a value 
from 0 to 4 for each of 4 variables, namely the amounts of 
bone, marrow, cartilage, and remaining collagen carrier. 
Statistics
We tested tendon mechanics with two-way ANOVA, using 
loading status (Botox or no Botox) and drug treatment as 
independent factors. Peak force served as the predetermined 
primary variable. 95% confidence intervals (CIs) for the treat-
ment effects were calculated separately for loaded tendons 
and unloaded tendons.
Screw fixation was tested by one-way ANOVA. Peak pull-
out force served as the predetermined primary variable. For 
calculation of the CI for treatment effects, controls were com-
pared with all etanercept groups combined. 
The area of the induced ectopic ossicle, and an estimate of 
its mineral density, were tested by one-way ANOVA. Histo-
logical scores were tested by Kruskall-Wallis test, followed 
by Mann-Whitney test for intergroup comparisons. We used 
PASW 18.0 software.
 
Results 
Tendon healing
Load protection by use of Botox reduced the peak force by 
almost two-thirds in both control rats and etanercept-treated 
rats, but there was no statistically significant effect of etaner-
cept (Figure 1). For the loaded tendons, the CI for the treat-
ment effect of etanercept ranged from a decrease in force of 
11% to an increase of 29%. For the load-protected tendons, 
the range was between a decrease of 25% and an increase of 
9%. Similar results were seen for stiffness and energy uptake 
(Table 1).
Bone healing
Screw peak pull-out force was not statistically significantly 
influenced by any of the etanercept treatment regimes (Figure 
2). The CI for the treatment effect of etanercept ranged from a 
Figure 1. Peak force (N) at tensile 
testing of transected tendons that 
were allowed to heal either with 
voluntary loading or with muscle 
paralysis induced by Botox.
Table 1. 95% confidence limits for the difference 
between means for mechanical properties of tran-
sected tendons (etanercept minus control). Values 
are expressed as percent of control (percent change 
from etanercept). The tendons were allowed to heal 
with voluntary loading or with muscle paralysis 
induced by Botox
  Lower Mean  Upper
Loaded 
  Peak force  –11  9  29
 Stiffness  –21  5  31
 Energy  –14  16  45
Botox 
  Peak force  –25  -8  9
 Stiffness  –27  -9  9
 Energy  –23  -3  16
Figure 2. Data from pull-out testing of screws 14 days after insertion in the proximal tibial metaphysis. 
Etanercept was given early, late, or continuously over the 14-day period. 308  Acta Orthopaedica 2012; 83 (3): 305–310
decrease in force of 25% to an increase of 18%. Similar results 
were obtained for stiffness and energy uptake (Table 2).
Ectopic bone formation
Histology showed new-formed ossicles in all cases. They con-
sisted of a shell of woven bone surrounding a marrow cavity 
with hematopoesis and fat cells. Within the woven bone, iso-
lated chondrocyte-like cells were sometimes seen, but these 
were rare. Continuous areas of cartilage matrix were never 
seen. 
The total area of the formed ossicle on the radiographs was 
not significantly different in the 3 treatment groups, as shown 
by one-way ANOVA (p = 0.06) (Figure 3). Therefore, to 
increase power, the etanercept groups were pooled and com-
pared with the controls by a t-test, which showed a larger total 
area with etanercept treatment, compared to the controls (p = 
0.02) (Figure 4 and Table 3). However, no statistically signifi-
cant effect was seen on the amount of bone within the ossicle, 
as estimated by radiodensity with a higher threshold (Figure 
3 and Table 3).
Qualitative blind scoring indicated effects on the amount or 
density of bone (p = 0.02) and the amount of remaining col-
lagen (p = 0.02) (Table 4). Post hoc testing showed that the 
amount of bone was higher in the etanercept groups than in 
Table 2. 95% confidence limits for the difference 
between means for screw fixation (the etaner-
cept groups combined minus controls). Values are 
expressed as percent of control (percent change 
from etanercept)
  Lower Mean  Upper
Peak force, N  –25  –3  18
Stiffness, N/mm  –22  4  29
Energy, Nmm  –24  1  25
Figure 3. Ossicles induced by BMP-2 in a collagen scaffold. Row A: 
control. Row B: continuously etanercept-treated. Column I: raw image. 
Column II: low threshold (ossicle size). Column III: high threshold (esti-
mate of bone density).
Figure 4. Radiographic data from rh-BMP 2 implants, with two different 
gray-scale thresholds for blind examination. Ossicle size (A) was mea-
sured with a low threshold, and “bone area” (B) with a higher thresh-
old, giving a visual impression of being related to bone density. For 
comparison, both estimates are presented in mm2. Ossicle size was 
larger with etanercept treatment (pooled; p = 0.02).
Table 3. 95% confidence limits for the difference 
between means for radiographic data describ-
ing ossicles induced by BMP-2 (both the etaner-
cept groups combined minus controls). Values are 
expressed as percent of control (percent change 
from etanercept)
  Lower Mean  Upper
Ossicle size  5  28  51
Bone area  –11  30  71
Table 4. Histological scoring of endochondral ossification: median (min–max). The 
scale goes from 0 (no prevalence) to 3 (high prevalence). The p-values are from 
Kruskall-Wallis test
  Control  Early  Continuous  Combined   p-value
Bone  1 (1–2)  2 (1–3)  3 (1–3)  2 (1–3)  0.02
Marrow  3 (2–3)  3 (2–3)  2 (1–3)  2 (1–3)  0.1
Cartilage  1 (0–2)  1 (0–2)  1 (0–2)  1 (0–2)  0.9
Collagen scaffold  2 (1–2)  1 (0–1)  1 (0–2)  1 (0–2)  0.02Acta Orthopaedica 2012; 83 (3): 305–310   309
the controls (p = 0.008 for continuous treatment and p = 0.06 
for early treatment). The amount of remaining collagen carrier 
was reduced in the etanercept groups (p = 0.2 for continuous 
treatment and p = 0.004 for early treatment). Scores for carti-
lage and marrow were similar in the different groups.
 
Discussion
With reasonable confidence, from our results we can exclude 
the possibility that etanercept has moderate to strong nega-
tive effects on metaphyseal bone and tendon healing. Previ-
ous tendon healing experiments with similar protocols and of 
comparable power showed that NSAID treatment had statis-
tically significantly negative effects (Virchenko et al. 2004), 
suggesting that etanercept is less detrimental, although no 
direct comparison has been made. 
We believe that the etanercept was given at a relevant dose, 
for two reasons. Firstly, we used a dose that has previously 
been shown to clearly modify disease processes in several 
rat models (Boettger et al. 2008, Zanella et al. 2008, Hsu and 
Chang 2010). Secondly, as a positive control in the present 
experiment, etanercept increased bone formation in intra-
muscular BMP 2 implants. However, we cannot definitively 
exclude the possibility that the doses tested were irrelevant.
Results for tendon healing in the rat model used might also 
be relevant for ligaments. For example, NSAIDs have similar 
effects on the healing of rat tendons and ligaments. To our 
knowledge, the effects of TNF-α signaling on the healing of 
these tissues have not been described, possibly because they 
appear to be weak. 
In a study with intramuscular BMP-2 implants in mice, 
etanercept was found to increase the amount of ectopic bone 
formed (Eguchi et al. 2010). In that study, no cartilage was 
seen, but the authors postulated that cartilage formation had 
preceded bone formation. We saw isolated chondrocyte-like 
cells, but no cartilage, and the bone structure resembled fetal, 
woven bone. This suggests that the bone had formed directly 
without any endochondral process. It has been shown in simi-
lar models that direct bone formation predominates if high 
doses of BMP are given (Murata et al. 1999). Thus, our results 
may not be valid for endochondral bone formation during 
fracture repair. Moreover, metaphyseal bone healing and ecto-
pic bone formation probably originate from different cells. In 
metaphyseal marrow, MSCs and osteoblast progenitors may 
be abundant, whereas ectopic bone formation may be depen-
dent on recruitment of MSCs from surrounding muscle or 
from the circulation.
The pathophysiological role of TNF-α signaling during 
healing is unclear, although it is known that TNF-α expres-
sion increases soon after injury (Kon et al. 2001). Deletion 
of TNF-α receptors in mice impairs bone healing, both in 
shaft fractures and after marrow ablation, which indicates that 
TNF-α signaling is required for good healing (Gerstenfeld et 
al. 2001). It appears that TNF-α aids in MSC recruitment—
and also in the transition from cartilage to bone via chondro-
cyte apoptosis and osteoclast recruitment (Gerstenfeld et al. 
2003). On the other hand, local injection of TNF-α reduced 
the amount of cartilaginous callus in rat rib fractures, indicat-
ing that high levels of TNF-α are detrimental (Hashimoto et 
al. 1989).
The interpretation of our findings is limited by moderately 
wide confidence intervals, the use of only single time points, 
and especially by our incomplete knowledge of how results in 
rats would relate to humans. 
To conclude, our observations do not support the idea that 
blocked TNF-α signaling poses a serious risk to healing of 
metaphyseal fractures or tendon injuries.
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